Moderna opens in Madrid its first laboratory outside the U.S. capable of producing all of its messenger RNA vaccines

Moderna opens in Madrid its first laboratory outside the U.S. capable of producing all of its messenger RNA vaccines

The company Moderna will inaugurate next Thursday in Madrid its first laboratory of Vaccine Quality Assays for messenger RNA vaccines outside the United Statesat an event to be attended, among others, by the President of the Government, Pedro Sánchez, and the Minister of Health, José Miñones.

This demonstrates the great commitment that the biotech company has done for Spain, according to sources from the company, since this new laboratory located in Madrid will make Spain, together with the United States, the only country capable of completing the production process of all its mRNA vaccines.

The laboratory will occupy the OM Infinito building, next door to that of Spanish pharmaceutical company Rovi, with which Moderna has signed a collaboration agreement to increase the manufacturing capacity of its sera against covid-19 and whose investment amounts to 500 million euros.


A woman receives a vaccine

Incorporation of sera

For the time being, it sticks to these vaccines because they are the ones that are marketed, although the agreement, for a duration of ten years, contemplates the incorporation of all sera mRNAs the U.S. company is working on in strategic areas such as cancer, respiratory or rare diseases.

With the new facilities, whose inauguration coincides with the celebration of the immunization week, a new phase is added, that of the quality controlprior to the distribution of its drugs in more than 60 countries, which consolidates the biotech company as one of the world’s leading companies in this field. leading producers mRNA vaccines in the world.

In addition to the President of the Government and the Minister of Health, the event is expected to be attended by the Ambassador of the United States, Julissa Reynoso; the Madrid Minister of Economy and Finance, Javier Fernández-Lasquetty, as well as representatives of other state institutions, scientific societies, patients and the pharmaceutical industry.

Kayleigh Williams